Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Dyslipidemia intervention in metabolic syndrome: emphasis on improving lipids and clinical event reduction.

Lavie CJ, Milani RV, O'Keefe JH.

Am J Med Sci. 2011 May;341(5):388-93. doi: 10.1097/MAJ.0b013e31821483fa. Review.

PMID:
21519201
2.

Managing the dyslipidemia of metabolic syndrome: beyond statin therapy.

Jialal I, Smith G.

Metab Syndr Relat Disord. 2012 Jun;10(3):159-60. doi: 10.1089/met.2012.1500. Epub 2012 May 8. No abstract available.

PMID:
22568574
3.

Obesity and lipids.

Miller WM, Nori-Janosz KE, Lillystone M, Yanez J, McCullough PA.

Curr Cardiol Rep. 2005 Nov;7(6):465-70. Review.

PMID:
16256017
4.

Treatment of dyslipidemia to reduce cardiovascular risk in patients with multiple risk factors.

Ballantyne CM.

Clin Cornerstone. 2007;8 Suppl 6:S6-13. Review.

PMID:
17948362
5.
6.

[Lipid-lowering treatment in metabolic syndrome].

Stulc T, Cecka R.

Vnitr Lek. 2009 Jul-Aug;55(7-8):626-30. Review. Czech.

PMID:
19731866
7.
8.

Combination lipid therapy in type 2 diabetes mellitus.

Vergès B.

Expert Opin Pharmacother. 2011 Jun;12(9):1393-403. doi: 10.1517/14656566.2011.558503. Epub 2011 Feb 16. Review.

PMID:
21323502
9.

Management of dyslipidemia in the metabolic syndrome.

Tan KC.

Cardiovasc Hematol Disord Drug Targets. 2007 Jun;7(2):99-108. Review.

PMID:
17584044
10.

Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis.

Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B.

Atherosclerosis. 2011 Aug;217(2):492-8. doi: 10.1016/j.atherosclerosis.2011.04.020. Epub 2011 Apr 27. Review.

PMID:
21592479
11.
12.

[Efficacy studies].

Pedro-Botet J, Flores-Le Roux JA.

Clin Investig Arterioscler. 2014 Jul;26 Suppl 1:17-9. doi: 10.1016/S0214-9168(14)70021-X. Spanish.

PMID:
25043542
13.

Pathogenesis and management of the dyslipidemia of the metabolic syndrome.

Raal FJ.

Metab Syndr Relat Disord. 2009 Apr;7(2):83-8. doi: 10.1089/met.2008.0079. Review.

PMID:
19400742
14.

[Indications for the combination of pravastatin and fenofibrate according to the type of dyslipidemia].

Núñez-Cortés JM.

Clin Investig Arterioscler. 2014 Jul;26 Suppl 1:31-4. doi: 10.1016/S0214-9168(14)70024-5. Spanish.

PMID:
25043545
15.

Lipid management: maximising reduction of cardiac risk.

Webb J, Gonna H, Ray KK.

Clin Med (Lond). 2013 Dec;13(6):618-20. doi: 10.7861/clinmedicine.13-6-618. Review. No abstract available.

PMID:
24298114
16.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

17.

Management of dyslipidemia in the metabolic syndrome: recommendations of the Spanish HDL-Forum.

Ascaso J, Gonzalez Santos P, Hernandez Mijares A, Mangas Rojas A, Masana L, Millan J, Pallardo LF, Pedro-Botet J, Perez Jimenez F, Pintó X, Plaza I, Rubiés J, Zúñiga M.

Am J Cardiovasc Drugs. 2007;7(1):39-58. Review. Erratum in: Am J Cardiovasc Drugs. 2007;7(4):302.

PMID:
17355165
18.

Pharmacotherapy of mixed dyslipidemia in the metabolic syndrome.

Nakajima K.

Curr Clin Pharmacol. 2010 May;5(2):133-9. Review.

PMID:
20156152
19.

Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

Keating GM.

Am J Cardiovasc Drugs. 2011 Aug 1;11(4):227-47. doi: 10.2165/11207690-000000000-00000. Review.

PMID:
21675801
20.

Atherogenic dyslipidemia.

Hayden MR.

J Cardiometab Syndr. 2006 Summer;1(3):166-7. No abstract available.

Supplemental Content

Support Center